Chung Byung Ha, Kim Bo-Mi, Doh Kyoung Chan, Cho Mi-La, Kim Kyoung Woon, Yang Chul Woo
Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea Seoul, Korea.
Transplant Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
PLoS One. 2017 Feb 28;12(2):e0172536. doi: 10.1371/journal.pone.0172536. eCollection 2017.
The aim of this study was to investigate the protective effect of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] on effector CD4+ T cells or on inflammatory cytokine-induced injury in human renal proximal tubular epithelial cells (HRPTEpiC).
First, we investigated the effect of 1,25(OH)2D3 on CD4+ T cell proliferation. Second, we examined the effect of 1,25(OH)2D3 on inflammatory cytokine secretion or fibrosis in HRPTEpiC induced by inflammatory cytokines or activated CD4+ T cells using ELISA and real-time PCR. Lastly, we compared urine inflammatory-cytokine (IL-6, IL-8) or KIM-1 levels in kidney transplant recipients low serum 25-hydroxyvitamin D (25(OH)D) group (< 20 ng/mL) (n = 40) and normal 25(OH)D group (n = 50).
Pre-incubation with 1,25(OH)2D3 significantly reduced the percentages of Th1 and Th17 cells compared to that of Th0 condition (P < 0.05 for each). In contrast, 1,25(OH)2D3 increased the proportion of Th2 and Treg cells in a dose-dependent manner (P < 0.05 for each). Treatment of HRPTEpiC with inflammatory cytokines (TNF-α, IL-17, and TGF-β) or effector CD4+ T cells resulted in increased production of IL-6, IL-8, or KIM-1 from HRPTEpiC in a dose-dependent manner. However, treatment with 1,25(OH)2D3 significantly reduced the level of these cytokines (P < 0.05 for all). Western blot analysis demonstrated that the mTOR/STAT3/ERK pathway was downregulated by 1,25(OH)2D3 in HRPTEpiC. Furthermore, the concentrations of urine IL-6/creatinine (P < 0.05) and Kim-1/creatinine (P < 0.05) were higher in the low 25(OH)D group than in the normal 25(OH)D group in kidney transplant recipients.
The results of this study suggests that vitamin D may have a significant role in the regulation of inflammation in allograft tissue in kidney transplant recipients.
All participants provided written informed consent in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Board of Seoul St. Mary's Hospital (KC13TNMI0701).
本研究旨在探讨1α,25 - 二羟基维生素D3 [1,25(OH)2D3] 对效应性CD4+ T细胞或对人肾近端小管上皮细胞(HRPTEpiC)中炎性细胞因子诱导损伤的保护作用。
首先,我们研究了1,25(OH)2D3对CD4+ T细胞增殖的影响。其次,我们使用酶联免疫吸附测定(ELISA)和实时定量聚合酶链反应(real-time PCR)检测了1,25(OH)2D3对炎性细胞因子或活化的CD4+ T细胞诱导的HRPTEpiC中炎性细胞因子分泌或纤维化的影响。最后,我们比较了肾移植受者中低血清25 - 羟基维生素D(25(OH)D)组(< 20 ng/mL)(n = 40)和正常25(OH)D组(n = 50)的尿炎性细胞因子(IL - 6、IL - 8)或肾损伤分子 - 1(KIM - 1)水平。
与Th0状态相比,预先用1,25(OH)2D3孵育可显著降低Th1和Th17细胞的百分比(各P < 0.05)。相反,1,25(OH)2D3以剂量依赖性方式增加Th2和调节性T细胞(Treg)的比例(各P < 0.05)。用炎性细胞因子(肿瘤坏死因子 - α、IL - 17和转化生长因子 - β)或效应性CD4+ T细胞处理HRPTEpiC导致HRPTEpiC中IL - 6、IL - 8或KIM - 1的产生呈剂量依赖性增加。然而,用1,25(OH)D3处理可显著降低这些细胞因子的水平(所有P < 0.05)。蛋白质免疫印迹分析表明,1,25(OH)2D3在HRPTEpiC中下调了哺乳动物雷帕霉素靶蛋白(mTOR)/信号转导和转录激活因子3(STAT3)/细胞外信号调节激酶(ERK)通路。此外,肾移植受者中低25(OH)D组的尿IL - 6/肌酐(P < 0.05)和KIM - 1/肌酐(P < 0.05)浓度高于正常25(OH)D组。
本研究结果表明,维生素D可能在肾移植受者同种异体移植组织炎症调节中起重要作用。
所有参与者均按照《赫尔辛基宣言》提供了书面知情同意书。本研究获得了首尔圣母医院机构审查委员会的批准(KC13TNMI0701)。